COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?

Cooper Companies (COO) reported fiscal Q2 2025 revenue of $1 billion (up 6.3% YoY) and adjusted EPS of $0.96 (up 14% YoY), exceeding expectations, driven by MyDay lens demand and surgical portfolio strength. Despite macroeconomic headwinds, the company reaffirmed its outlook, projecting full-year revenue of $4.107-$4.146 billion and adjusted EPS of $4.05–$4.11; however, softness in the fertility market and global inventory corrections present challenges, leading to a revised contact lens market growth assumption of 4-6%.

Analysis

Cooper Companies (COO) reported a robust fiscal second quarter 2025, with revenues reaching $1 billion, a 6.3% year-over-year increase, and adjusted earnings per share of $0.96, up 14% YoY, surpassing analyst expectations. This performance was driven by strong demand for MyDay lenses, accelerating MySight adoption (growing 35% in Q2 and on track for over $100 million in FY25 sales), and strength in its surgical portfolio, where CooperSurgical reported 13% revenue growth (10% organic), supported by the obp Surgical acquisition (31% growth) and PARAGARD (18% growth). Despite these positive results and reaffirmed full-year revenue guidance of $4,107-$4,146 million and adjusted EPS of $4.05–$4.11, the company faces headwinds. These include softness in the fertility market, with growth expectations revised down to low single digits for fiscal 2025, and persistent global inventory corrections, which led to a revised contact lens market growth assumption of 4-6%. COO's stock has underperformed, declining 25.7% year-to-date, contrasting with gains from competitors Johnson & Johnson (JNJ) and Alcon (ALC), and the broader market. However, COO demonstrates operational leverage with gross margins improving 100 basis points to 68% and operating margins rising 100 basis points to 25%. The company maintains a healthy balance sheet, expecting $350–$400 million in free cash flow for fiscal 2025, a leverage ratio of 1.9X, and actively repurchased $40.6 million in shares during Q2. Valuation appears attractive, with COO trading at a 16X forward P/E ratio, below its industry and at a five-year low. Potential risks include $4 million in tariff-related costs in fiscal 2025, potentially rising to a 3% EPS headwind in fiscal 2026, and ongoing FX volatility.

Key Decisions for Investors

• Investors should consider the attractive valuation and strong underlying product momentum, particularly in MyDay and MySight, against the backdrop of significant year-to-date share price underperformance.
• Monitor the progress of inventory corrections across the vision care sector and the recovery in the fertility market, as these are key to unlocking COO's growth potential and justifying its reaffirmed guidance.
• Evaluate the company's strategies to mitigate tariff impacts and FX volatility, as these could pose headwinds to future earnings if not effectively managed, despite current operational efficiencies and share buybacks.